Yet Again, Ozempic Could Soon Get Even Better for Novo Nordisk Stock
16/9 13:05
As if it wasn't obvious by the endless fountain of ebullient headlines, Ozempic is the gift that keeps on giving for Novo Nordisk (NYSE: NVO) and its investors. Ozempic's active ingredient, semaglutide, received initial approval from the FDA for treating type 2 diabetes. It's now...